76 results about "Virus antigen" patented technology

The utility model relates to the field of antigen detection kits, and discloses an infectious bovine rhinotracheitis virus antigen detection kit which comprises a box body, a roller is rotatably connected to the bottom side in the box body, a clamping groove is formed in the upper side of the roller, a clamping pin is connected to the clamping groove in a clamping mode, and a placing table is fixedly connected to the upper side of the clamping pin. A plurality of swab placing grooves, an extraction tube placing groove and a detection card placing groove are respectively formed in the upper side of the placing table, the plurality of swab placing grooves, the extraction tube placing groove and the detection card placing groove are distributed in a circumferential array, and sampling swabs are arranged on the inner sides of the plurality of swab placing grooves; according to the utility model, a plurality of groups of sampling swabs, sample extraction tubes and antigen detection cards which are distributed in a circumferential array manner are placed on the placement table, so that when sampling personnel go to cattle for sampling one by one, the sampling personnel can rotate to detection materials such as the next group of antigen detection cards and the like only by pressing down the push rod and switching the angle of the placement table, and the operation is convenient and the use is simple.

The invention relates to the technical field of immunodetection, and discloses a bovine nodular skin disease virus chimeric antigen and application thereof in an ELISA (enzyme-linked immuno sorbent assay) detection kit. According to the chimeric antigen, a gene of a dominant region of a bovine nodular skin disease virus antigen is selected to design a chimeric antigen gene, meanwhile, sequence optimization is performed, a chemical synthesis method is used for synthesizing a coding gene of the chimeric antigen of the bovine nodular skin disease virus, and then the chimeric antigen is obtained in a prokaryotic expression mode. An ELISA antibody detection kit developed on the basis of the chimeric antigen has extremely high sensitivity and specificity, can rapidly and specifically detect bovine nodular skin disease virus antibodies in serum, is suitable for monitoring and checking the nodular skin diseases of cattle in large-scale breeding, and has relatively high practical value.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.

The present invention relates to the field of biomedicine technology, and specifically discloses an mRNA based on the CP protein gene of fish nervous necrosis virus, a vaccine, and a preparation method and application thereof. The present invention provides an mRNA of fish nervous necrosis virus, the nucleotide sequence of which is shown in SEQ ID NO: 1, and the structure includes a 5' untranslated region, a signal peptide sequence, an NNV virus antigen coding region, a 3' untranslated region and polyA. The mRNA vaccine contains the ORF sequence of the capsid protein CP gene that is resistant to NNV virus infection. The results of animal safety tests on the fish nervous necrosis virus mRNA vaccine prepared by the present invention show that the vaccine is safe and effective, and is convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral nervous necrosis in marine cultured fish.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.

The invention relates to the technical field of genetic engineering, in particular to identification of a new insertion site of a self-assembled protein cage nanoparticle antigen epitope and application of the new insertion site in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between 62nd-63rd amino acids of an Encapsulin protein fragment after amino acid sequence modification, and / or the 62nd-63rd amino acids are replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The application discloses an influenza virus universal nanoparticle vaccine and a preparation method thereof. The application designs an influenza virus antigen by using an influenza virus matrix protein 2 extracellular domain (M2e) and hemagglutinin (HA), and forms a trimer structure by fusing a foldon motif at the C terminal of the antigen. On this basis, the application prepares an influenza virus antigen multimeric complex through a GvTagOpti / SdCatcher system, and prepares the influenza virus universal nanoparticle vaccine which can be inoculated through the respiratory system and has good immunoprotective effect by taking the obtained multimeric complex as an immunogen. The nanoparticle vaccine disclosed by the application not only has good immunoprotective effect and can prevent infection of different subtypes of influenza viruses after inoculation, but also has a simple preparation method, high safety and can be quickly applied to clinical trials.

The invention belongs to the technical field of nano-antibodies, and particularly relates to a nano-antibody for resisting H1N1 influenza virus NA protein as well as a preparation method and application of the nano-antibody. The method comprises the following steps: by taking A / Puerto Rick / 8 / 34 (H1N1) influenza virus as a research object, purifying and inactivating the influenza virus through sucrose density gradient centrifugation, immunizing alpaca by taking the influenza virus as an immunogen, and screening by utilizing a phage display technology to obtain a high-affinity spectral anti-avian influenza virus NA protein nano antibody. Animal experiments show that the nano antibody has a good prevention effect when acting on A / Puerto Radio / 8 / 34 (H1N1) influenza virus infected C57 mice. Through preparation of the anti-influenza virus NA protein nano antibody, not only is a material provided for development of an H1N1 influenza virus diagnostic reagent, but also a thought is provided for identification of H1N1 subtype influenza virus epitope and vaccine design.

The invention relates to a respiratory syncytial virus antigen detection kit, and relates to the technical field of biomedical detection, the respiratory syncytial virus antigen detection kit comprises a respiratory syncytial virus antigen detection reagent strip, the reagent strip comprises a sample pad, a colloidal gold conjugate pad and a nitrocellulose membrane which are connected in sequence, the colloidal gold combination pad is coated with a colloidal gold labeled nano antibody which is specifically combined with the respiratory syncytial virus, and the nano antibody comprises a CDR sequence as shown in SEQ ID NO: 2-4. The kit provided by the invention has the effects of high detection sensitivity, good specificity and short detection time.

The present invention relates to the field of biomedicine technology, and specifically discloses a circular mRNA vaccine for marine farmed fish, a preparation method thereof, and an application thereof. The circular mRNA in the present invention includes an IRES untranslated region, a signal peptide sequence, and an NNV virus antigen coding region connected in sequence; in the preparation process, a DNA template with a T7 promoter is first synthesized by a chemical method, and T7 RNA transcription is performed using the DNA template. The transcribed RNA is adenylated, and then circularized and connected by T4 RNA enzyme 2 to generate circular RNA, and finally purified by ethanol precipitation to obtain NNV-B1 circular mRNA. The NNV-B1 circular mRNA vaccine prepared by the present invention has been shown by the results of the animal safety test to be safer and more effective, convenient and simple to use clinically, and has broad application prospects in the prevention and control of viral neuronecrosis.

The invention relates to a sample treatment liquid for respiratory virus antigen detection and a preparation method thereof. The sample treatment liquid comprises a phosphate buffer solution, 0.05-0.5 g / L of sodium caseinate, 1-20 g / L of bovine serum albumin, 10-50 mL / L of a surfactant, 1-10 g / L of guanidine hydrochloride, 3.72-37.2 g / L of an ethylene diamine tetraacetic acid disodium salt diaqueous solution, 1-5 mL / L of a CL preservative, 1-5 mL / L of a BND bacteriostatic agent and 900-988 mL / L of sterile deionized water. The method has the advantage of good sample stability.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

Abstract The present disclosure provides a method for vaccinating a subject against a mucosal virus 5 infection, comprising administering to the subject an immunologically effective amount of an intranasal booster, wherein the intranasal booster comprises detoxified Escherichia coli labile toxin (LT) and an antigen from the mucosal virus, and wherein the subject has been previously primed. An intranasal vaccine composition comprising an immunologically effective amount of a mucosal virus antigen adjuvanted with a detoxified Escherichia coli labile toxin (LT) is also .0 provided. ~22~ Sep 2023 Abstract 5 2023237105 27 ~22~

1. The name of the design product: kit (virus antigen detection). 2. The use of the design product: for containing each component of the kit for detecting avian leukosis virus. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best shows the design points: perspective view 1. 5. The design for which protection is sought contains color.

Based on a monkey pox virus immunodiagnosis technology based on up-conversion and long-afterglow nanoparticles, the preparation method comprises the following steps: preparing the long-afterglow and up-conversion nanoparticles by adopting a hydrothermal method and a solvothermal method respectively, and constructing the antibody-modified UCNP and PLNP nano probe by utilizing an EDC-NHS cross-linking system after carboxylation modification. The two nanoprobes and an antigen form an immune complex in a double antibody sandwich mode, the UCNPs is excited to emit light at the wavelength of 980 nm, the UCNPs and the PLNPs generate an LRET effect, an obvious signal peak is detected at the wavelength of 700 nm, and the fluorescence signal intensity is in direct proportion to the antigen content. The detection technology is portable and high in sensitivity, the detection limit is as low as the pg / ml level, and the monkey pox virus antigen standard substance can be detected in the range of 1 mg / ml to 1 ng / ml. According to the immunodetection technology provided by the invention, the detection of various pathogens can be realized by replacing antibody combinations aiming at different antigen epitopes, and the application potential in the aspect of infectious disease diagnosis is huge.

The invention relates to a Chikungunya virus antigen and dengue virus antigen detection kit, a preparation method and a detection method. The kit comprises a chikungunya virus antibody marked by quantum dot microspheres, a dengue virus antibody marked by quantum dot microspheres, a sample loading solution and immunochromatography detection test paper. The kit and the detection method based on the fluorescence immunochromatography are high in sensitivity, strong in specificity and good in stability, can realize synchronous quantitative detection of chikungunya virus antigen and dengue virus antigen, effectively improve the detection efficiency, are simple and efficient in detection operation process, can report a result within 15 minutes, are suitable for on-site rapid detection, and have good application prospects. And a new means is provided for prevention, control, diagnosis and treatment of chikungunya virus and dengue virus.

The application discloses a high-recognition and low-scattering quantum dot tubular assembly structure immunochromatography probe and a preparation method and application thereof, and first prepares a nickel-hydrazine complex nanorod, performs etching to obtain a one-dimensional hollow tubular silicon dioxide nanotube, performs mercapto-modification, constructs an oil-soluble tubular assembly through multi-layer assembly of quantum dots, transfers the assembly to an aqueous solvent through an efficient alkylsilane phase transfer strategy, deposits a thin and dense silicon oxide layer on the surface of the assembly to protect the assembly, and simultaneously performs carboxylation and coupling of a novel coronavirus antigen N protein antibody based on the silicon oxide layer to obtain a fluorescent probe. The one-dimensional hollow tubular material is used as a carrier of a signal tag, and due to double optimization of signal amplification effect and immunoreaction efficiency, the sensitivity of a lateral flow immunochromatography platform is improved, and important scientific basis is provided for early discovery, early treatment and early prevention and control of virus infection.

The present application relates to a detection kit for the diagnosis and screening of nasopharyngeal carcinoma. The detection kit comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting an EB virus antigen-antibody by means of a colloidal gold labeling method. The present application further relates to the use of the detection card and the EB virus antigen-antibody in the preparation of a detection kit or detection card for the diagnosis and screening of nasopharyngeal carcinoma.

The utility model provides a fish multi-virus antigen joint detection kit, which relates to the technical field of antigen detection, and comprises a plurality of outer shells, each outer shell is provided with a connecting assembly used for connecting two outer shells together, the top of each outer shell is provided with an observation window and a sample adding hole, and the observation window is provided with a plurality of through holes. One end of each outer shell is open, an inner shell is detachably installed in each outer shell in a sliding mode, a drawing handle is fixedly installed at the outer end of each inner shell, the free end of each drawing handle extends out of the corresponding outer shell, and a locking assembly is arranged between the inner end of each inner shell and the other end of the corresponding outer shell. According to the fish virus detection kit, the number of the outer shells and the types of the detection test strips can be freely combined according to the number and the types of fish viruses to be detected, and waste of the outer shells and the detection test strips is avoided.

The present disclosure provides polycistron vaccines, as well as methods of making and using the same, for preventing infection or propagation in a subject, or for reducing the severity of a disease caused by influenza and / or SARS-Cov-2 virus. The polycistron vaccines of the present disclosure may be administered by intramuscular, intranasal, or inhalation route. In one particular embodiment, the invention provides a recombinant adenovirus comprising at least two different exogenous oligonucleotides capable of stimulating an immune response in a subject. Each oligonucleotide independently comprises an oligonucleotide encoding an influenza or SARS-Cov-2 virus antigen.

The invention discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence derived from a non-structural protein NS7 of FCV with a coding sequence of a SpyTag peptide fragment through a coding sequence of a linker, and cloning to a baculovirus transfer vector to obtain a recombinant plasmid; and finally, integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. According to the invention, NS7 is selected as a core immunogen to guide an immune system to generate high cellular immune response, so that the defect of an existing vaccine in removing viruses in cells is overcome; meanwhile, T cell epitopes with specificity are selected from the sequence of NS7 as immunogens, so that the variability of antigens among different strains and immune escape caused by virus antigen drift can be avoided, and wider-spectrum protection is provided.

The application discloses a kind of NbP1 single-domain antibody, TAT-NbP1 fusion single-domain antibody and purposes thereof, belong to biological medicine technical field.The NbP1 single-domain antibody of the application is used to specifically bind new coronavirus PLpro antigen, the NbP1 single-domain antibody is composed of framework region FR and three complementarity determining regions CDR1, CDR2 and CDR3;The amino acid sequence of CDR1 is as shown in SEQ ID NO.1, the amino acid sequence of CDR2 is as shown in SEQ ID NO.2, the amino acid sequence of CDR3 is as shown in SEQ ID NO.3.TAT-NbP1 fusion single-domain antibody is the fusion protein of NbP1 single-domain antibody and HIV-1 virus TAT peptide segment.The NbP1 single-domain antibody and TAT-NbP1 fusion single-domain antibody provided by the application have both antiviral and anti-inflammatory activities, and are safe, which provides a new idea for treating SARS-CoV-2 infection and developing anti-SARS-CoV-2 drugs.

The utility model discloses a display device for the working principle of popular science vaccines. The display device comprises an exhibition stand, a display assembly and a control assembly, the top of the exhibition stand is provided with a control area and an exhibition area. The display assembly is arranged in the display area and comprises a display cabinet, the display cabinet is provided with a back plate and a top plate, a grabbing cavity is formed in the back plate and the top plate, a display module and an identification module are arranged on the back plate, a grabbing module is arranged on the top plate, and a plurality of virus models are placed in the grabbing cavity; the control assembly is arranged in the control area; the capturing task is issued through the display module, the control assembly controls the capturing module to capture the virus model, the identification module identifies the virus model and matches the identification result with the capturing task, and the display module plays the preset content according to the matching result. According to the utility model, by combining with an interactive small game, participants can know different viruses, antigens and antibodies and know immune response after human body vaccine injection, so that the enthusiasm of the participants can be fully aroused, the interactivity is strong, and the science popularization effect is good.